Background-We previously reported marked inhibitory effects of recombinant apolipoprotein (apo) A-I Milano /phospholipid complex (A-I Milano /PC) on neointimal lesions in balloon-injured iliofemoral arteries of hypercholesterolemic rabbits. In this study, we tested the hypothesis that apo A-I Milano /PC would inhibit aortic atherosclerosis in apo E-deficient mice. Methods and Results-Thirty-five apo E-deficient mice fed a high-cholesterol diet were included in the study. Control mice were killed at 20 (nϭ8) or 25 (nϭ7) weeks. 
S
everal epidemiological and clinical studies have demonstrated an inverse relationship between coronary heart disease and circulating levels of HDL cholesterol and its major apoprotein, apolipoprotein (apo) A-I. [1] [2] [3] [4] [5] [6] Because relationships observed in epidemiological studies do not necessarily prove a cause and effect, it has been debated whether HDL and apo A-I are simply markers of reduced risk or have direct antiatherogenic effects. Several lines of evidence gathered in the past few years have suggested that HDL and apo A-I may have direct antiatherogenic effects. [7] [8] [9] [10] [11] Apo A-I Milano is a naturally occurring mutant of apo A-I, with a cysteine-to-arginine substitution at position 173 that is associated with freedom from vascular disease and longevity in its carriers despite markedly reduced HDL and elevated triglyceride levels. [12] [13] [14] [15] [16] We previously demonstrated that recombinant apo A-I Milano /phospholipid complex (A-I Milano /PC) significantly reduces neointimal lesions in the balloon-injured iliofemoral arteries of cholesterol-fed rabbits. 17 Similar results have since been reported by Soma et al 18 with a periadventitial carotid injury model in cholesterol-fed rabbits. Because atherosclerotic lesions in rabbits differ from those in humans, we sought to determine the effects of genetically engineered recombinant apo A-I Milano /PC on aortic atherosclerosis in apo E-deficient mice, which develop atherosclerotic lesions that more closely resemble the advanced lesions observed in humans.
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Methods
Apo E-deficient mice (C57BL/6J strain, aged 5 weeks, 18 to 20 g) obtained from Jackson Laboratory (Bar Harbor, Me) were fed a high-fat, high-cholesterol (atherogenic) diet containing 21% (wt/wt) fat and 0.15% cholesterol throughout the duration of the experiment. Control mice were killed at 20 (nϭ8) and 25 (nϭ7) weeks of age. With the use of a special mice restrainer (Scanbur A-S) and a 30-gauge needle, mice were administered 40 mg/kg apo A-I Milano /PC dissolved in 0.5 mL saline (nϭ15) or PC only (nϭ5) through the tail vein every other day from 20 weeks until killed at 25 weeks, for a total of 18 injections each. The recombinant apo A-I Milano /PC preparation used in this study has been described previously. 17 All research involving these animals was approved by the Institutional Animal Care and Use Committee and conformed to the Guiding Principles in the Care and Use of Laboratory Animals established by the council of the American Physiology Society.
Before death, mice were anesthetized with enflurane inhalation, and 100 of 300 L of blood was obtained from the retro-orbital plexus through heparin-coated capillaries (Fisher Scientific) and collected in an EDTA-treated Vacutainer tube (Becton Dickinson) for serum lipoprotein analysis, determination of apo A-I Milano levels, and detection of antibodies against apo A-I Milano using methods described previously. 17 Mice were killed 8 to 24 hours after the last injection. Serum was stored at Ϫ70°C until analysis. Serum cholesterol was measured with an enzymatic technique. 17 Lipoproteins were further characterized in 2 mice receiving apo A-I Milano /PC through adjustment of 300 L of serum to dϭ1.21 kg/L followed by a 48-hour centrifugation (Beckman 50.3 rotor at 40 000 rpm in an Optima ultracentrifuge at 1°C). The lipoprotein fraction was dialyzed against phosphate-buffered saline and separated with size-exclusion chromatography (Sepharose 6) on an FPLC (Pharmacia-Upjohn). 22 The cholesterol concentration in the fractions was determined with fluorometry. 22, 23 Peak fractions representative of VLDL, LDL, and HDL were also subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis for visualization of the respective apo contents in the fractions. 22, 23 The elution pattern of isolated VLDL, LDL, and HDL fractions had been determined beforehand to indicate the borders between the respective fractions.
The circulating levels of apo A-I Milano and antibodies to apo A-I Milano were determined by ELISA as described previously.
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Tissue Preparation and Histological Analysis
After anesthesia with enflurane, the mice were killed, and their hearts and aortas were perfusion-fixed with 4% paraformaldehyde, 5% sucrose, and 20 mmol/L EDTA at physiological pH for 10 minutes. The heart and proximal aorta were excised and embedded in OCT compound (Tissue-Tek), frozen on dry ice, and then stored at Ϫ70°C until sectioning. Serial 10-m-thick sections (every fifth section from the middle of the ventricle until the appearance of aortic valve and every second section from the appearance to the disappearance of the aortic valve leaflets) were collected on poly-D-lysine-coated slides, stained with oil-red O and hematoxylin, and counterstained with Fast Green. Quantification of atheromatous lesions in the proximal aorta was performed with computer-assisted morphometry with image analysis software (Optimas 5.1; Bioscan) and expressed as the average of lesion areas from six sections per mice. The descending thoracic aorta and abdominal aorta (up to bifurcation of common iliac arteries) were removed, stored overnight in formal-sucrose fixative, split open longitudinally, and stained with Sudan IV to visualize the extent of atherosclerosis. Quantification of the percentage of aortic surface covered by atheroma was performed with computer-assisted planimetry of the Sudan IV-positive areas. The interobserver and intraobserver variabilities of these measurements were Ͻ1.5% and Ͻ0.5%, respectively.
In selected sections, immunohistochemical staining was performed using monoclonal rat anti-mouse Mac-1 antibody (Boehringer-Mannheim Biochemicals) as a specific marker for monocyte/macrophages.
Measurement of Cholesterol Efflux In Vitro
To determine the effect of apo A-I Milano /PC on cellular cholesterol efflux, we used Fu5AH hepatoma cell lines preloaded with radiolabeled cholesterol exposed to apo A-I Milano /PC, PC-free apo A-I Milano , or PC only for 4 hours. At the end of incubation, the medium was removed, and the remaining cellular lipids were extracted with isopropanol. Aliquots of cellular extract and medium were measured by liquid scintillation, and the fractional efflux of cholesterol into the medium was determined as a measure of cholesterol efflux-promoting capacity. This method for determination of cholesterol efflux has been described in detail by de La Llera Moya et al. 24 
Statistical Analysis
Data are presented as meanϮSD. Group comparisons were made using an unpaired t test or ANOVA followed by Newman-Keuls test with a two-tailed PՅ.05 value considered to be significant.
Results
Extent of Aortic Atherosclerosis
In the untreated control mice, aortic atherosclerosis increased by 59% from 20 to 25 weeks (11Ϯ1% versus 17Ϯ5% of the aortic surface, Pϭ.004) (Table and Fig 1, top) . In comparison with 20-week-old untreated control mice, mice receiving PC only also demonstrated a 36% increase in aortic atherosclerosis at 25 weeks (11Ϯ1% versus 15Ϯ4%; Pϭ.01). In contrast, aortic atherosclerosis did not progress in mice treated with apo A-I Milano/PC at 25 weeks compared with untreated control mice at 20 weeks (11Ϯ1% versus 10Ϯ4%). Aortic atherosclerosis at 25 weeks was significantly less in apo A-I Milano /PC-treated mice than in untreated control mice (PϽ.01; ANOVA) and PC only-treated mice (PϽ.05; ANOVA).
Lipid Content in Aortic Sinus Atheromatous Plaque
In the untreated control mice, the lipid content in the aortic sinus plaque increased from 22Ϯ8% of the plaque area at 20 weeks to 32Ϯ6% at 25 weeks (Pϭ.03) ( 
Macrophage Content in Aortic Sinus Plaque
From 20 to 25 weeks, there was no significant increase in macrophage content in the untreated control mice (10.8Ϯ2% versus 13.2Ϯ6% of plaque area) or PC only-treated mice (10.8Ϯ2% versus 11Ϯ2%) (Table and Fig 1, bottom) . In contrast, macrophage content was reduced by 46% in apo A-I Milano /PCtreated mice at 25 weeks compared with untreated control mice at 20 weeks (10.8Ϯ2% versus 5.8Ϯ2.9%; Pϭ.03).
Serum Cholesterol and Apo A-I Milano Levels
Serum cholesterol levels were 25.7Ϯ7.5 mmol/L (1029Ϯ301 mg/dL) at 20 weeks and 27.3Ϯ4.4 mmol/L (1091Ϯ179 mg/dL) at 25 weeks in untreated control mice (Table) . The serum cholesterol levels were 29.6Ϯ5.6 mol/L (1181Ϯ35 mg/dL) and 23Ϯ5.9 mmol/L (918Ϯ235 mg/dL) in mice receiving PC only and apo A-I Milano /PC, respectively. Serum cholesterol levels did not differ significantly between the groups. The lipoprotein distribution of cholesterol between untreated controls and apo A-I Milano /PC-treated mice were similar except for a slight increase in the cholesterol content of the HDL fraction in apo A-I Milano /PC-treated mice (Fig 2) . The apo A-I band in the apo A-I Milano /PC-treated mice was faint, but a strong band of 60 to 70 kD was detected in these mice, suggesting the presence of apo A-I Milano dimer despite reducing conditions. At the time of death, apo A-I Milano was detectable in all mice (nϭ15) receiving apo A-I Milano /PC but in none of the controls. The apo A-I Milano level averaged 312Ϯ124 g/mL in the 5 mice killed at 8 hours after the last injection and 14Ϯ13 g/mL in 10 mice killed at 24 hours after the last injection. Antibodies against apo A-I Milano were detected in the sera of mice receiving apo A-I Milano (nϭ3) but in none of the control mice (nϭ3).
Effect of Apo A-I Milano /PC on Cholesterol Efflux
As shown in Fig 3, apo A-I Milano /PC promoted cholesterol efflux in a dose-dependent fashion (nϭ6). In contrast, PC only (nϭ6) or PC-free apo A-I Milano (nϭ6) had no effect on cholesterol efflux.
Effect of High-Dose Apo A-I Milano /PC
Three additional mice received a higher dose of apo A-I Milano /PC (80 mg/kg per dose) for a total of 18 injections over 5 weeks. The extent of aortic atherosclerosis at 25 weeks was further reduced to 3.6Ϯ0.2% of the aortic surface despite a serum cholesterol level of 28.2Ϯ5.9 mmol/L (1129Ϯ237 mg/dL) with a corresponding further reduction in the macrophage content in aortic sinus plaques to 3.2Ϯ0.4% of the plaque area. A comparable dose of PC only (nϭ3) had no significant effect on aortic atherosclerosis compared with 25-week untreated control mice (16Ϯ4.6% versus 17Ϯ5% of aortic surface; PϭNS)
Discussion
The results of this study demonstrate that recombinant apo A-I Milano /PC prevents progression of aortic atherosclerosis in apo E-deficient mice fed a high-cholesterol diet despite persistent and severe hypercholesterolemia. Preliminary observations involving 3 additional mice receiving a higher dose (80 mg/kg per dose) suggest that apo A-I Milano /PC may also induce regression of aortic atherosclerosis, although this finding needs further confirmation. The present findings extend our previously described protective effects of recombinant apo A-I Milano /PC on neointimal lesions in balloon-injured ileofemoral arteries of hypercholesterolemic rabbits. 17 In contrast to the present study, we did not detect a change in the total cholesterol content of the aorta in the rabbit model; however, this difference may have resulted from fewer injections (5 versus 18) and lower doses per injection (10 versus 40 mg/kg) used in the rabbit model compared with the mouse model in this study. 17 The results of this study are consistent with the beneficial effects of intravenous injection of homologous HDL/VHDL and apo A-1 in hypercholesterolemic rabbits 7, 11 and the protective effects of apo A-I transgene expression on diet-induced atherosclerosis in apo E-deficient mice. 9, 10 Taken together, these experimental observations provide compelling evidence for the direct antiatherogenic effects of apo A-I and HDL.
The apo E-deficient mouse is a recently introduced experimental model created through gene targeting and homologous recombination that develops hypercholesterolemia and atherosclerotic lesions on regular mouse chow within a few weeks of birth. 19 -21 The time course of lesion development as well as their severity and extent are enhanced with high-cholesterol chow. 19 -21 These mice develop atherosclerotic lesions ranging from early fatty streaks, lipid-rich lesions, and fibrofatty and calcified lesions closely resembling the various stages and complexities of human atherosclerosis. 19 -21 The lesions tend to occur earliest in the aortic sinuses, later involving other parts of the aorta and its branches, including intramyocardial coronary arteries and carotid arteries. 19 -21 Because of the rapid time course of lesion development and the close similarity of lesions to those of advanced human atherosclerosis, we chose to evaluate the effects of recombinant apo A-I Milano /PC in this murine model.
Mechanisms of Action of Apo A-I Milano /PC
The precise mechanisms by which apo A-I Milano /PC produces its antiatherogenic effects are not fully understood. The beneficial effects of HDL and apo A-I have been attributed to promotion of reverse cholesterol transport, inhibition of LDL oxidation, scavenging of lipid peroxides from peripheral tissues, modulation of inflammatory response by inhibition of complement polymerization, and promotion of fibrinolysis. [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] The fact that protective effects of apo A-I Milano /PC on aortic atherosclerosis were observed despite the persistence of hypercholesterolemia indicates that antiatherogenic effects are not mediated by a major reduction in severity of hypercholesterolemia. In this study, apo A-I Milano /PC reduced the lipid and inflammatory cell (monocyte/macrophage) content of the more advanced atheromatous plaques and promoted cellular cholesterol efflux in vitro. In contrast, PC only did not prevent the progression of aortic atherosclerosis, nor did it reduce the lipid or macrophage content in the advanced aortic sinus atherosclerotic lesions. Thus, the favorable effects of apo A-I Milano /PC observed in this study cannot be attributed solely to the PC component of apo A-I Milano /PC. Furthermore, PC only and PC-free apo A-I Milano did not promote cellular cholesterol efflux in vitro. This finding is consistent with the complementary role of apo A-I and PC for stimulation of cholesterol efflux in which apo A-I acts as an acceptor for cellular cholesterol and PC acts as a sink, as proposed by Atger et al. 35 These results are generally consistent with those observed in the rabbit iliofemoral and carotid injury model. 17, 18 A decrease in the lipid and inflammatory cell (macrophage) content in the atheromatous plaques as well as in vitro cholesterol efflux-promoting effects of apo A-I Milano /PC are consistent with reverse cholesterol-promoting effects of apo A-I Milano /PC. The cysteine-for-arginine substitution at position 173 in the amino acid sequence of apo A-I Milano results, among other changes, in a higher kinetic affinity of apo A-I Milano for lipids and an easier dissociation from lipid/protein complexes, which might contribute to its increased efficiency for uptake of tissue lipids. 36 The precise molecular mechanisms by which apo A-I-containing particles and HDL mediate reverse cholesterol transport in vivo remain incompletely understood. It has recently been demonstrated that scavenger receptor type B class I, also known as SR-BI, acts as a putative HDL receptor mediating selective cellular uptake of HDL cholesterol ester in steroidogenic tissues and liver in vitro and in vivo, suggesting that SR-BI may be involved in HDL metabolism and cholesterol homeostasis. 37, 38 These observations are further supported by the recent demonstration that HDL-dependent cellular cholesterol efflux is markedly enhanced by overexpression of SR-BI in several different cell types in vitro and that SR-BI is expressed in atheroma in apo E-deficient mice. 39 In experimental animals such as apo E-deficient mice, as well as in humans, oxidative modification of lipoproteins is believed to play an important role in atherogenesis. 28, 40, 41 The proatherogenic effects of oxidized lipoproteins have been attributed to their ability to stimulate inflammatory cell (monocyte) attachment, migration, and recruitment into the arterial wall, transformation of monocytes to macrophages and foam cells through the scavenger receptor pathway, T cell activation, and endothelial dysfunction. 29, 30, 42, 43 The inflammatory cells recruited into the arterial wall have been shown to modulate production of growth factors and cytokines that influence smooth muscle cell migration, proliferation, and matrix secretion. 44, 45 Several in vitro studies have suggested that HDL may inhibit the formation or alter the properties of oxidatively modified lipoproteins. 28 These antioxidant effects have been attributed to the binding of pro-oxidant transition metals by apo A-I 25 and to paraoxonase and platelet-activating factor acetylhydrolase, two enzymes carried by apo A-I-and apo J-containing HDL particles. 28 Furthermore, it has been suggested that HDL may sequester oxidized lipids from LDL, thereby limiting apo B modification. 26 Thus, the favorable effects of apo A-I Milano /PC observed in this study may have resulted from enhancement of reverse cholesterol transport, antioxidant effects, or other undefined mechanisms.
Potential Limitations
Several potential limitations of the present study must be considered. The results in apo-E-deficient mice, in which hypercholesterolemia is largely due to elevated levels of triglyceride-rich VLDL, may differ from that in humans, in whom an elevated LDL level is more common. However, several recent studies in humans have highlighted the important prognostic and potential therapeutic implications of triglyceride-rich lipoproteins, including small dense LDL in coronary heart disease. 46 -50 Although LDL-lowering therapy in randomized trials has been shown to reduce coronary events, the continued occurrence of coronary events in a substantial number of subjects despite LDL-lowering therapy strongly suggests the importance of non-LDL lipoproteins and other risk factors in atherosclerotic vascular disease. 49 Moreover, the magnitude of hypercholesterolemia in these mice is considerably greater than that observed in humans. Nevertheless, the atherosclerotic lesions in these mice closely resemble those of human, and it is very likely that an intervention that is effective in the presence of profound hypercholesterolemia may indeed be even more effective in the presence of lesser degrees of hypercholesterolemia. An immune response to apo A-I Milano/PC could potentially limit the efficacy, but that is less likely to be an issue when human subjects are evaluated. Even in mice, efficacy did not appear to be blunted even though antibodies against apo A-I Milano were detected at the end of the experiment in apo A-I Milano /PC-treated animals. Finally, we did not address the issue of whether the antiatherogenic efficacy of apo A-I Milano /PC differs substantively from that of apo A-I wild-type /PC in this particular model. However, we demonstrated previously that in cholesterol-fed rabbits, reconstituted HDL containing human wild-type apo A-I produced a modest 25% reduction in neointimal lesion formation (nϭ10, PϭNS versus controls) (unpublished observations) compared with a 70% reduction in neointimal lesion area using recombinant apo A-I Milano /PC. 17 However, further studies will be necessary to more completely address this issue.
Potential Clinical Implications
The favorable effects of recombinant apo A-I Milano /PC on the extent of atherosclerosis and lipid/macrophage content observed in this study suggest that an antiatherogenic strategy using apo A-I Milano /PC or possibly other forms of HDL-containing apo A-I holds promise for inhibition of the progression of atherosclerosis and/or stabilization of rupture-prone (lipid and inflammatory cell-or macrophage-rich) atherosclerotic plaques. Although the clinical trials of LDL lowering with statins have been successful in reducing coronary heart disease events by 30% to 40%, many patients continue to experience disease progression and coronary events despite LDL lowering. 49 Further reduction in clinical events will require additional therapies that focus on non-LDL types of lipoproteins and non-lipid-related risk factors for atherosclerosis. 49 Unlike lipid-lowering drugs targeted to reduce cholesterol levels, apo A-I appears to exert its beneficial effects via mechanisms other than a reduction in cholesterol levels. Thus, a therapeutic strategy based on apo A-I may be complementary to LDL lowering. Further exploration of apo A-I and HDL as a potential therapeutic strategy appears warranted.
